Allergan Seeks Quick Vraylar Turnaround After US FDA Refuses To File
Executive Summary
Supplemental application for negative symptoms associated with schizophrenia has robust data, Datamonitor Healthcare analyst suggests, but was incomplete.
You may also be interested in...
Acadia Revives Nuplazid’s Chances In Schizophrenia With Negative Symptom Data
After a Phase III failure in refractory schizophrenia, Acadia has Phase II data showing efficacy in negative symptoms of the disease, an unmet need. It plans a pivotal study in 2020.
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.